Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis
Open Access
- 6 June 2022
- journal article
- research article
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 2(74),p. 25-32
Abstract
Flow-mediated vasodilation (FMD) has been demonstrated to be a useful, non-invasive tool for the detection of endothelial dysfunction in atherosclerotic cardiovascular disease, the leading cause of mortality in end-stage kidney disease. The Fas/Fas ligand system of apoptosis resulting from activation of the caspase cascade- contributes to the pathophysiology of atherosclerosis. This ‘apoptotic’ system plays a central role in immune homeostasis. Vascular endothelial cells and inflammatory cells are the main resources of the Fas ligand. In this study, we aimed to investigate the role of soluble Fas ligand (sFasL) as a marker of FMD in peritoneal dialysis (PD) patients. Methods. A total of 43 patients undergoing maintenance PD and 40 healthy donors were enrolled in this cross-sectional observational study. Demographics, anthropometric measurements and clinical examinations were obtained. Endothelial function was evaluated by FMD of the brachial artery with high-resolution ultrasonography. Serum sFasL concentrations were measured with an enzyme-linked immunosorbent assay kit. Results. The enrolled partisipants were devited on 2 groups: PD patients who had been treated at least 12 weeks (group 1; mean age 41±14 years, M/F: 22/21) and gender matched 40 healthy controls (group 2; mean age 50±12 years, M/F: 19/20). The forearm FMD and serum sFasL levels were significantly lower in PD patients (3.95±2.01 vs 8.83 ± 6.17; p<0.001 and 54 ± 24 vs 73 ± 30; p=0.001). Forearm FMD was correlated with sFasL (r=0.289; p=0.008), age, BMI and uric acid (r= 0,32; p=0.003, respectively), hemoglobin (r= 0,293; p=0.007), calcium (r= 0,26; p=0.016), phosphate (r=- 0,250; p=0.023), magnesium (r= 0,255; p=0.020), 24 h SBP (r=- 0,257; p=0.019), creatinine and iPTH (r=- 0.50 and r=- 0,45; p<0.001, respectively). After adjustment for age, the stepwise multivariate analysis showed sFasL was independently associated to FMD (β: 0.180; p=0.03, CI: 0.078-0.314). vs 73 ± 30; p=0.001). Conclusions. sFasL may be used as a simple screening marker for endothelial dysfunction in PD patients.Keywords
This publication has 20 references indexed in Scilit:
- A Randomized Study of Allopurinol on Endothelial Function and Estimated Glomular Filtration Rate in Asymptomatic Hyperuricemic Subjects with Normal Renal FunctionClinical Journal of the American Society of Nephrology, 2011
- Flow-Mediated Vasodilation in End-Stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2011
- Assessment of atherosclerosis: the role of flow-mediated dilatationEuropean Heart Journal, 2010
- Prevention of Overweight and Obesity: How Effective is the Current Public Health ApproachInternational Journal of Environmental Research and Public Health, 2010
- Membrane-bound Fas ligand only is essential for Fas-induced apoptosisNature, 2009
- Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular RiskArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis: The Rotterdam Coronary Calcification StudyAtherosclerosis, 2006
- Cardiovascular risk factors in chronic kidney diseaseKidney International, 2005
- The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney International, 2002
- Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisThe Lancet, 1992